Jim Simons T Scan Therapeutics, Inc. Transaction History
Renaissance Technologies LLC
- $56.7 Billion
- Q2 2024
A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 80,000 shares of TCRX stock, worth $403,200. This represents 0.0% of its overall portfolio holdings.
Number of Shares
80,000
Previous 47,000
70.21%
Holding current value
$403,200
Previous $373,000
25.47%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding TCRX
# of Institutions
80Shares Held
36.3MCall Options Held
0Put Options Held
0-
Eco R1 Capital, LLC San Francisco, CA5MShares$25.2 Million1.03% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$22.5 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.4MShares$22.2 Million0.05% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$15.1 Million0.53% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$14 Million0.22% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $95.4M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...